'Happy Feet' benefit Tamiflu treatment

Share this article:
Roche dipped a webbed foot into entertainment industry partnerships with a tie-in to the animated penguin romp “Happy Feet” that stands to benefit its Tamiflu treatment.

The company's Flu Facts campaign features characters from the movie, in print, TV, online and banner ads that direct viewers to  www.flufacts.com. Ads for the campaign were handled by InVentiv's GSW, online was executed by Avenue A|Razorfish.

While movie tie-ins are old hat for consumer goods makers, the partnership is a likely first for a pharmaceutical company.

“Our goal is to join the public health community in raising awareness about how Americans can minimize the incidence of seasonal flu, which brings significant health and economic burdens to the country each year,” said Mike McGuire, Roche VP, anti-infectives.

The campaign includes  TV ads airing on all the major networks. Print ads are running in magazines including Fitness, Family Circle and Martha Stewart Living. Banners will also appear in movie theaters and airports.

The campaign is not Roche's first innovative online effort for Tamiflu. In the branded arena, Roche has, for the past several years, sponsored the Tamiflu Desktop Flu Tracker, a downloadable device featuring animated characters and a map showing current rates of flu prevalence across the US.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...